Related Experiment Video
Updated: May 28, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Macrophage-specific autotaxin deficiency promotes hepatic steatosis and inflammation in diet-induced MASLD
Soyeong Park1, Sihyun Jeong1, Yunna Lee1
1Department of Pharmacy, College of Pharmacy, Pusan National University, Busan, Republic of Korea.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disorder in which dysregulated inflammation plays a central role. We previously reported that macrophage-specific deletion of autotaxin (ATX) exacerbates inflammatory responses, including lipopolysaccharide -induced peritonitis and interleukin-10 deficiency-mediated colitis in mice. Moreover, circulating ATX levels are elevated in patients with MASLD. This study aimed to determine whether macrophage-specific ATX deficiency influences MASLD progression. To this end, MASLD was induced using amylin liver nonalcoholic steatohepatitis (AMLN) diet in macrophage-specific ATX knockout (AtxΔME/ΔME) and wild-type (Atx+/+) mice. ATX deficiency in macrophages promoted lipid droplet deposition in hepatocytes and hepatic triglyceride accumulation, thereby aggravating liver steatosis. Serum alanine aminotransferase, aspartate transaminase, and total cholesterol levels were significantly higher in AtxΔME/ΔME AMLN mice compared with Atx+/+ AMLN mice. In addition, ATX deletion increased proinflammatory cytokine production in both Kupffer cells and hepatocytes. Notably, the expression of sterol regulatory element-binding transcription factor 1 and carbohydrate-responsive element-binding protein was elevated in AtxΔME/ΔME AMLN mice. Collectively, these findings demonstrate that macrophage-specific ATX deficiency accelerates MASLD progression by enhancing inflammation and upregulating lipogenic transcription factors, leading to increased hepatic lipid accumulation.NEW & NOTEWORTHY This study reveals a protective role of macrophage-derived autotaxin (ATX) in liver homeostasis, demonstrating that its cell-specific deletion exacerbates hepatic steatosis, inflammation, and injury in a diet-induced metabolic dysfunction-associated steatotic liver disease model. Mechanistically, loss of ATX enhances proinflammatory cytokine production in Kupffer cells and hepatocytes, while upregulating lipogenic transcription factors, such as Srebf1 and Chrebp. These findings highlight macrophage-derived ATX as a critical regulator of hepatic lipid metabolism by restraining inflammation-driven lipogenesis.
Insights
Macrophage-specific deletion of autotaxin (ATX) worsens metabolic dysfunction-associated steatotic liver disease (MASLD) by increasing liver inflammation and lipid accumulation. This highlights ATX
Area of Science:
- Hepatology
- Immunology
- Metabolic Diseases
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) involves significant inflammation.
- Macrophage autotaxin (ATX) deficiency exacerbates inflammatory conditions.
- Elevated circulating ATX levels are observed in MASLD patients.
Purpose of the Study:
- To investigate the impact of macrophage-specific ATX deficiency on MASLD progression.
- To elucidate the role of ATX in liver inflammation and lipid metabolism within MASLD.
Main Methods:
- Induction of MASLD using the amylin liver non-alcoholic steatohepatitis (AMLN) diet in mice.
- Comparison between macrophage-specific ATX knockout (AtxΔME/ΔME) and wild-type (Atx+/+) mice.
- Analysis of liver steatosis, inflammatory markers, and lipogenic gene expression.
Main Results:
- Macrophage ATX deficiency aggravated liver steatosis, evidenced by increased lipid droplet deposition and hepatic triglyceride accumulation.
- Serum liver enzymes (ALT, AST) and cholesterol levels were significantly elevated in AtxΔME/ΔME mice.
- Pro-inflammatory cytokine production increased in Kupffer cells and hepatocytes, alongside elevated SREBP-1 and ChREBP expression.
Conclusions:
- Macrophage-specific ATX deficiency accelerates MASLD progression.
- This acceleration is driven by enhanced inflammation and upregulated lipogenic transcription factors.
- Targeting macrophage ATX may offer a therapeutic strategy for MASLD.
